RELB and cancer: Noteworthy, the described RelB signature partially resembles a tolerogenic signature of migratory DCs promoting resistance to checkpoint therapy in cancer, so-called ‘mature DCs enriched in immunoregulatory molecules’ (mregDCs)19.